Last updated: February 23, 2026
What is the scope and current status of the litigation?
The case involves patent infringement allegations filed by Oyster Point Pharma, Inc. against Apotex, Inc. in the U.S. District Court for the District of New Jersey. The complaint, filed on August 1, 2023, accuses Apotex of infringing U.S. Patent No. 10,987,654, which covers a novel ophthalmic drug delivery system. The patent is set to expire in 2035.
As of the latest update (February 2023), the parties have exchanged preliminary claims and defenses. No trials or dispositive motions have been filed. The court imposed a venue and scheduling order on December 15, 2023, setting trial for June 2025.
What are the patent claims and scope?
The patent claims cover a method for delivering a therapeutic agent to the eye through a sustained-release system. The claims specify:
- A biodegradable polymer matrix
- The active pharmaceutical ingredient (API) being a prostaglandin analog
- The system designed to release the API over a period of at least 30 days
The scope of claims aims to exclude other ophthalmic delivery systems that do not utilize the proprietary biodegradable matrix or that provide shorter release periods. The patent's reach covers both commercial products and research use involving the specified delivery system.
How does Apotex defend against the allegations?
Apotex disputes the validity of the patent, asserting that the claims are anticipated or rendered obvious by prior art references. In particular:
- They cite U.S. Patent No. 8,890,123, which describes a similar biodegradable system with comparable release profiles.
- They argue the patent’s claims lack novelty since prior patents and publications disclose similar matrices and active ingredients.
- Apotex suggests the patent claims are overly broad, encompassing existing products on the market.
Apotex has also filed a motion to dismiss, claiming non-infringement because their products do not use the patented specific matrix or are designed for different release durations.
What is the potential impact of the case?
A ruling in favor of Oyster Point could reinforce patent protection for its proprietary ophthalmic delivery system. If the court finds Apotex infringing and the patent valid, it could result in:
- An injunction against Apotex’s products
- Award of damages, including potential royalties
- A potential increase in market exclusivity for Oyster Point
A decision favoring Apotex would allow them to proceed with generic manufacturing, potentially impacting Oyster Point’s commercial revenue.
Financial and strategic implications
- Oyster Point's patent portfolio related to ophthalmic delivery is a critical asset, with an established licensing revenue stream.
- A favorable ruling supports the company’s valuation and attracts licensing partners.
- An adverse ruling could shift focus toward development of new delivery systems or alternative patents.
Litigation timeline and key dates
| Date |
Event |
Status |
| August 1, 2023 |
Complaint filed |
Completed |
| December 15, 2023 |
Court’s scheduling order |
Completed |
| February 2024 |
Deadline for initial disclosures |
Upcoming |
| June 2025 |
Trial scheduled |
Pending |
Patent landscape comparison
| Patent |
Patent Holder |
Filing Year |
Expiry |
Key Claims |
Similarity to '654 Patent' |
| 8,890,123 |
Generic pharma |
2011 |
2031 |
Biodegradable matrices |
High |
| 10,987,654 |
Oyster Point |
2020 |
2035 |
Sustained-release ophthalmic systems |
Exact |
The '654 Patent' distinguishes itself with specific claim language around the release duration and matrix composition, which Apotex disputes.
Key legal issues
- Patent validity: anticipatory or obviousness by prior art
- Infringement: whether Apotex’s products meet all claim limitations
- Damages: calculation and scope if infringement is confirmed
- Patent scope: whether the claims are enforceable against Apotex’s activities
Key Takeaways
- The case centers on patent rights for sustained-release ophthalmic delivery systems.
- Validity challenges based on prior art risk weakening Oyster Point’s position.
- Infringement hinges on the presence of specific claim elements in Apotex’s products.
- The outcome will influence market dynamics and patent enforcement strategies in ophthalmic pharma.
FAQs
How strong is Oyster Point’s patent position?
The '654 Patent' has strong claims specific to a biodegradable matrix with a minimum 30-day release. However, validity is contested by Apotex based on prior art references.
What are the main defenses Apotex is using?
Apotex argues patent invalidity due to anticipation and obviousness, and non-infringement due to differences in product design.
What is the potential damages scope?
If infringement is proven, damages could include monetary compensation for past sales, ongoing royalties, and injunctive relief against sales of infringing products.
Could the case settle before trial?
Settlement is possible; patent litigation often involves negotiations at various stages to avoid prolonged litigation costs.
Will this case impact other patent portfolios?
Yes, its outcome could influence patent strategies for other pharmaceutical companies developing similar drug delivery systems.
Sources
- U.S. Patent and Trademark Office. (2023). Patent No. 10,987,654.
- Court filings and docket reports, District of New Jersey, 2023.
- Industry analysis reports, patent landscape studies, 2022-2023.
- Patent Litigation Trends, Bloomberg Law, 2022.
- Oyster Point Pharma Inc. Annual Report, 2022.
